Ordulu Zehra, Kammin Tammy, Brand Harrison, Pillalamarri Vamsee, Redin Claire E, Collins Ryan L, Blumenthal Ian, Hanscom Carrie, Pereira Shahrin, Bradley India, Crandall Barbara F, Gerrol Pamela, Hayden Mark A, Hussain Naveed, Kanengisser-Pines Bibi, Kantarci Sibel, Levy Brynn, Macera Michael J, Quintero-Rivera Fabiola, Spiegel Erica, Stevens Blair, Ulm Janet E, Warburton Dorothy, Wilkins-Haug Louise E, Yachelevich Naomi, Gusella James F, Talkowski Michael E, Morton Cynthia C
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA.
Department of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Boston, MA 02115, USA.
Am J Hum Genet. 2016 Nov 3;99(5):1015-1033. doi: 10.1016/j.ajhg.2016.08.022. Epub 2016 Oct 13.
In this exciting era of "next-gen cytogenetics," integrating genomic sequencing into the prenatal diagnostic setting is possible within an actionable time frame and can provide precise delineation of balanced chromosomal rearrangements at the nucleotide level. Given the increased risk of congenital abnormalities in newborns with de novo balanced chromosomal rearrangements, comprehensive interpretation of breakpoints could substantially improve prediction of phenotypic outcomes and support perinatal medical care. Herein, we present and evaluate sequencing results of balanced chromosomal rearrangements in ten prenatal subjects with respect to the location of regulatory chromatin domains (topologically associated domains [TADs]). The genomic material from all subjects was interpreted to be "normal" by microarray analyses, and their rearrangements would not have been detected by cell-free DNA (cfDNA) screening. The findings of our systematic approach correlate with phenotypes of both pregnancies with untoward outcomes (5/10) and with healthy newborns (3/10). Two pregnancies, one with a chromosomal aberration predicted to be of unknown clinical significance and another one predicted to be likely benign, were terminated prior to phenotype-genotype correlation (2/10). We demonstrate that the clinical interpretation of structural rearrangements should not be limited to interruption, deletion, or duplication of specific genes and should also incorporate regulatory domains of the human genome with critical ramifications for the control of gene expression. As detailed in this study, our molecular approach to both detecting and interpreting the breakpoints of structural rearrangements yields unparalleled information in comparison to other commonly used first-tier diagnostic methods, such as non-invasive cfDNA screening and microarray analysis, to provide improved genetic counseling for phenotypic outcome in the prenatal setting.
在这个令人兴奋的“新一代细胞遗传学”时代,在可操作的时间范围内将基因组测序整合到产前诊断中是可行的,并且可以在核苷酸水平上精确描绘平衡染色体重排。鉴于新生的从头平衡染色体重排患儿先天性异常风险增加,对断点进行全面解读可显著改善表型结果的预测,并为围产期医疗护理提供支持。在此,我们展示并评估了10例产前受试者平衡染色体重排的测序结果,这些结果与调控染色质结构域(拓扑相关结构域[TADs])的位置有关。通过微阵列分析,所有受试者的基因组材料被解读为“正常”,且其重排无法通过游离DNA(cfDNA)筛查检测到。我们系统方法的结果与不良结局妊娠(5/10)和健康新生儿(3/10)的表型相关。在表型-基因型关联之前,有两例妊娠终止,其中一例的染色体畸变预计临床意义不明,另一例预计可能为良性(2/10)。我们证明,结构重排的临床解读不应局限于特定基因的中断、缺失或重复,还应纳入人类基因组的调控结构域,这些结构域对基因表达的控制具有关键影响。如本研究详细所述,与其他常用的一线诊断方法(如非侵入性cfDNA筛查和微阵列分析)相比,我们检测和解读结构重排断点的分子方法可产生无与伦比的信息,从而在产前环境中为表型结果提供更好的遗传咨询。